English
Français
Deutsch
Italiano
Português
Русский
Español
ไทย
Türkçe
简体中文
日本語
한국어
हिन्दी
Topline
Drugmaker GSK on Wednesday announced promising preliminary results from a late-state trial of its RSV vaccine in people aged 50 to 59, offering hope of expanding access to the landmark shot and boosting efforts to combat the common and potentially deadly respiratory infection.
Key Facts
GSK said the vaccine, marketed as Arexvy, elicited an immune response in adults aged 50 to 59 who are at risk of RSV disease due to underlying medical conditions after a single dose.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
